These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 33105713)

  • 21. miR-410-3p promotes prostate cancer progression via regulating PTEN/AKT/mTOR signaling pathway.
    Zhang Y; Zhang D; Lv J; Wang S; Zhang Q
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2459-2465. PubMed ID: 29969630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
    Antonarakis ES; Keizman D; Zhang Z; Gurel B; Lotan TL; Hicks JL; Fedor HL; Carducci MA; De Marzo AM; Eisenberger MA
    Cancer; 2012 Dec; 118(24):6063-71. PubMed ID: 22674438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis.
    Cui Z; Gao H; Yan N; Dai Y; Wang H; Wang M; Wang J; Zhang D; Sun P; Qi T; Wang Q; Kang W; Jin X
    Aging (Albany NY); 2021 Apr; 13(8):12113-12128. PubMed ID: 33848262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
    Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
    Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proproliferative function of adaptor protein GRB10 in prostate carcinoma.
    Khan MI; Al Johani A; Hamid A; Ateeq B; Manzar N; Adhami VM; Lall RK; Rath S; Sechi M; Siddiqui IA; Choudhry H; Zamzami MA; Havighurst TC; Huang W; Ntambi JM; Mukhtar H
    FASEB J; 2019 Mar; 33(3):3198-3211. PubMed ID: 30379590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
    Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
    J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
    Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
    Patel R; Gao M; Ahmad I; Fleming J; Singh LB; Rai TS; McKie AB; Seywright M; Barnetson RJ; Edwards J; Sansom OJ; Leung HY
    J Clin Invest; 2013 Mar; 123(3):1157-75. PubMed ID: 23434594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
    Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
    Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN loss correlates with T cell exclusion across human cancers.
    Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
    BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
    Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
    Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?
    Ashrafizadeh M; Zarrabi A; Samarghandian S; Najafi M
    Eur J Pharmacol; 2020 Aug; 881():173226. PubMed ID: 32485246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
    Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
    Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
    Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG
    Clin Cancer Res; 2012 Feb; 18(4):1015-27. PubMed ID: 22114138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
    Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
    Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.